Andreas Lohri
Andreas Lohri publishes mostly in Pathology and Forensic Medicine, Oncology and Genetics, on topics such as Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and Lung Cancer Treatments and Mutations.
- World rank
- #1,031,843 of 7,710,434 ranked researchers
- Rank in Switzerland
- #17,710 of 80,918
- Works
- 113
- Citations
- 6.1k
- Citations per work
- 54.3
What does Andreas Lohri research?
Andreas Lohri's work is mostly in Medicine (60%), Biochemistry, Genetics and Molecular Biology (7%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences6759.5%
- Medicine6759.5%
- Everything else3833.5%
- Life Sciences87.0%
- 1Pathology and Forensic Medicine22% of their works
- 2Oncology13% of their works
- 3Genetics9% of their works
- 4Pulmonary and Respiratory Medicine9% of their works
- 5Molecular Biology7% of their works
- 6Radiology, Nuclear Medicine and Imaging6% of their works
Research topics
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cutaneous lymphoproliferative disorders research
- Esophageal Cancer Research and Treatment
Which keywords describe Andreas Lohri's research?
The keywords of their largest research topics: Rituximab, PET Imaging, Classification, Lymphoma, Prognostic Factors, Targeted Therapy, Chronic Lymphocytic Leukemia and Genomic Aberrations.
- Preoperative Chemoradiotherapy
- Esophageal Carcinoma
- Radiopharmaceuticals
- Prognostic Scoring System
- Kaposi's Sarcoma
- EGFR Mutations
- Genomic Aberrations
- Targeted Therapy
- Lymphoma
- PET Imaging
- Rituximab
- Classification
- Prognostic Factors
- Chronic Lymphocytic Leukemia
- ALK Inhibitors
- Epstein-Barr Virus
- Primary CNS Lymphoma
- Radioimmunotherapy
- Cutaneous Lymphomas
- Mycosis Fungoides
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 20 words, with their numbers
- Rituximab872 topics
- PET Imaging702 topics
- Classification621 topic
- Lymphoma621 topic
- Prognostic Factors322 topics
- Targeted Therapy262 topics
- Chronic Lymphocytic Leukemia251 topic
- Genomic Aberrations251 topic
- ALK Inhibitors181 topic
- EGFR Mutations181 topic
- Epstein-Barr Virus151 topic
- Kaposi's Sarcoma151 topic
- Primary CNS Lymphoma101 topic
- Prognostic Scoring System101 topic
- Radioimmunotherapy81 topic
- Radiopharmaceuticals81 topic
- Cutaneous Lymphomas71 topic
- Esophageal Carcinoma71 topic
- Mycosis Fungoides71 topic
- Preoperative Chemoradiotherapy71 topic
Where does Andreas Lohri work?
Andreas Lohri's main affiliation in the publication record is Kantonsspital Baselland, Switzerland.
How many publications and citations does Andreas Lohri have?
OpenAlex counts 113 works and 6,135 citations for Andreas Lohri, an h-index of 31, ranking #1,031,843 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Andreas Lohri. Posts are plain text and can be reported.